Compare CMTL & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMTL | VNRX |
|---|---|---|
| Founded | 1967 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.4M | 38.2M |
| IPO Year | N/A | N/A |
| Metric | CMTL | VNRX |
|---|---|---|
| Price | $3.25 | $0.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $6.00 | $3.17 |
| AVG Volume (30 Days) | 278.6K | ★ 2.6M |
| Earning Date | 01-12-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $499,528,000.00 | $1,472,007.00 |
| Revenue This Year | N/A | $55.33 |
| Revenue Next Year | $5.15 | $493.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.48 |
| 52 Week Low | $1.19 | $0.27 |
| 52 Week High | $4.88 | $0.94 |
| Indicator | CMTL | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.52 | 35.58 |
| Support Level | $3.00 | $0.27 |
| Resistance Level | $3.32 | $0.33 |
| Average True Range (ATR) | 0.20 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 88.33 | 31.95 |
Comtech Telecommunications Corp is a provider of modern communications solution incorporated in USA. The company is engaged in designing, developing, producing and marketing products, systems, and services for communications solutions. It is engaged in two business segments, Satellite and Space Communications and Terrestrial and Wireless Networks. It's Space and satellite is USA based providers of modems and high-power amplifiers, a market leader in troposcatter technologies, and serves some of the world's defense contractors and allied foreign governments. Terrestrial and Wireless Networks segment is a provider of next generation 911 infrastructure and solutions for state and local governments and carriers. Majority of sales are generated from Satellite and Space Communications segment.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.